Exosomes As Drug Delivery System in Gastrointestinal Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 10

PMID 36761427

Authors

Fangyuan Xie

Yueying Huang

Yangyang Zhan

Leilei Bao

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal cancer is one of the most common malignancies with relatively high morbidity and mortality. Exosomes are nanosized extracellular vesicles derived from most cells and widely distributed in body fluids. They are natural endogenous nanocarriers with low immunogenicity, high biocompatibility, and natural targeting, and can transport lipids, proteins, DNA, and RNA. Exosomes contain DNA, RNA, proteins, lipids, and other bioactive components, which can play a role in information transmission and regulation of cellular physiological and pathological processes during the progression of gastrointestinal cancer. In this paper, the role of exosomes in gastrointestinal cancers is briefly reviewed, with emphasis on the application of exosomes as drug delivery systems for gastrointestinal cancers. Finally, the challenges faced by exosome-based drug delivery systems are discussed.

References

Zhang H, Wang Y, Bai M, Wang J, Zhu K, Liu R . Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA. Cancer Sci. 2017; 109(3):629-641. PMC: 5834801. DOI: 10.1111/cas.13488. View

Lin H, Zhang L, Zhang C, Liu P . Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. J Cell Mol Med. 2020; 24(16):8930-8941. PMC: 7417713. DOI: 10.1111/jcmm.15524. View

Gebregiworgis T, Bhinderwala F, Purohit V, Chaika N, Singh P, Powers R . Insights into gemcitabine resistance and the potential for therapeutic monitoring. Metabolomics. 2019; 14(12):156. PMC: 6620022. DOI: 10.1007/s11306-018-1452-7. View

Kotmakci M, Cetintas V . Extracellular Vesicles as Natural Nanosized Delivery Systems for Small-Molecule Drugs and Genetic Material: Steps towards the Future Nanomedicines. J Pharm Pharm Sci. 2015; 18(3):396-413. DOI: 10.18433/j36w3x. View

Liang G, Kan S, Zhu Y, Feng S, Feng W, Gao S . Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int J Nanomedicine. 2018; 13:585-599. PMC: 5796471. DOI: 10.2147/IJN.S154458. View

Hsu H, Chen M, Baskaran R, Lin Y, Day C, Lin Y . Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 2017; 233(7):5458-5467. DOI: 10.1002/jcp.26406. View

Zhao K, Cheng X, Ye Z, Li Y, Peng W, Wu Y . Exosome-Mediated Transfer of circ_0000338 Enhances 5-Fluorouracil Resistance in Colorectal Cancer through Regulating MicroRNA 217 (miR-217) and miR-485-3p. Mol Cell Biol. 2021; 41(5). PMC: 8088270. DOI: 10.1128/MCB.00517-20. View

Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q . Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2020; 268:120546. DOI: 10.1016/j.biomaterials.2020.120546. View

Xiao L, Erb U, Zhao K, Hackert T, Zoller M . Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology. 2017; 6(6):e1319044. PMC: 5486185. DOI: 10.1080/2162402X.2017.1319044. View

10.

Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T . Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020; 14(3):539-555. PMC: 7053238. DOI: 10.1002/1878-0261.12629. View

11.

Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N . 5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. Cancer Sci. 2020; 111(9):3142-3154. PMC: 7469786. DOI: 10.1111/cas.14532. View

12.

Pitt J, Charrier M, Viaud S, Andre F, Besse B, Chaput N . Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol. 2014; 193(3):1006-11. DOI: 10.4049/jimmunol.1400703. View

13.

Tang Q, Yang S, He G, Zheng H, Zhang S, Liu J . Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett. 2022; 548:215823. DOI: 10.1016/j.canlet.2022.215823. View

14.

Zhou Y, Zhou W, Chen X, Wang Q, Li C, Chen Q . Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharm Sin B. 2020; 10(8):1563-1575. PMC: 7488356. DOI: 10.1016/j.apsb.2019.11.013. View

15.

Jiang X, Gao J . Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm. 2017; 521(1-2):167-175. DOI: 10.1016/j.ijpharm.2017.02.038. View

16.

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

17.

Zhou L, Li J, Tang Y, Yang M . Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p/ANXA2 axis. J Transl Med. 2021; 19(1):8. PMC: 7789760. DOI: 10.1186/s12967-020-02648-7. View

18.

Aspe J, Diaz Osterman C, Jutzy J, DeShields S, Whang S, Wall N . Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant. J Extracell Vesicles. 2014; 3. PMC: 3929070. DOI: 10.3402/jev.v3.23244. View

19.

Al Faruque H, Choi E, Kim J, Kim E . Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer. J Control Release. 2022; 347:330-346. DOI: 10.1016/j.jconrel.2022.05.012. View

20.

Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z . Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med. 2019; 23(8):4854-4865. PMC: 6653385. DOI: 10.1111/jcmm.14356. View